Search
CMSC 2026

Bugs and Drugs: Practical Management Considerations Around Infections and MS Disease Modifying Therapies

Moderator/Chair: Robert J. Fox , MD
Infections are associated with most MS disease modifying therapies, but the risks and related management strategies vary considerably. Our faculty of MS neurologists and advanced practice providers will review 1) what therapies have what infection risks, including rare infection risks; 2) risk factors for infections; and 3) practical risk mitigation and management strategies, including pre-treatment screening, clinical and laboratory monitoring, alternate interval administration, and de-escalation. All presentations will leverage published studies along with clinical experience, including illustrative case studies, and ending with a faculty discussion and audience Q&A. Attendees will gain the ability to recognize infectious complications related to MS disease modifying therapies and mitigate those risks. Level of Information: Intermediate, AdvancedInfections are associated with most MS disease modifying therapies, but the risks and related management strategies vary considerably. Our faculty of MS neurologists and advanced practice providers will review 1) what therapies have what infection risks, including rare infection risks; 2) risk factors for infections; and 3) practical risk mitigation and management strategies, including pre-treatment screening, clinical and laboratory monitoring, alternate interval administration, and de-escalation. All presentations will leverage published studies along with clinical experience, including illustrative case studies, and ending with a faculty discussion and audience Q&A. Attendees will gain the ability to recognize infectious complications related to MS disease modifying therapies and mitigate those risks. Level of Information: Intermediate, Advanced

Presentations in This Session

Infections with Steroids, ABCR, Fumarates, Natalizumab

Speaker/s: Hilary Young, PA-C

Infections with S1Ps, B Cell Depleters, Alemtuzumab, and Mavenclad

Speaker/s: Grace Worland, NP, MSN, MSCN

Infection Management Strategies: General, S1Ps, B Cell Depleters, Mavenclad

Speaker/s: Enrique Alvarez Alvarez, MD, PhD

Infection Management Strategies: Fumarates, Natalizumab, Alemtuzumab

Speaker/s: Robert J. Fox, MD